Vimarsana
Biggest News Aggregation in the World

Identifying Patients News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Identifying Patients. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Identifying Patients Today - Breaking & Trending Today

PreludeDx™ Presents New Data Demonstrating Utility of DCISionRT® to De-escalate Radiation Therapy for Women with DCIS - Vimarsana News

PreludeDx™ Presents New Data Demonstrating Utility of DCISionRT® to De-escalate Radiation Therapy for Women with DCIS

/PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in precision diagnostics for early-stage breast cancer, presented data on the use of DCISionRT® to...

The Week in Review: October 2-6 - Vimarsana News

The Week in Review: October 2-6

From new research on treatment-resistant major depression to strategies for supporting trauma-affected refugee youth, here are highlights from the week in Psychiatric Times.

High-Grade PVCs During Post-Exercise Recovery Linked to CV Mortality - Vimarsana News

High-Grade PVCs During Post-Exercise Recovery Linked to CV Mortality

Findings may help identify patients at increased risk High-grade exercise-induced premature ventricular contractions (PVCs) were both more common and had greater prognostic significance when they occurred during recovery after exercise rather than during exertion, a retrospective study found. Among adults who had no known cardiac disease and no indication for cardiac exercise stress testing, high-grade

FDA Approves Verzenio® (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer - Vimarsana News

FDA Approves Verzenio® (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer

/PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's (NYSE: LLY) Verzenio® (abemaciclib), in combination with...